Drug resistant patterns of invasive Streptococcus pneumoniae infections in the State of Florida in 2003 by Drennon, Michael T
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
2006
Drug resistant patterns of invasive Streptococcus
pneumoniae infections in the State of Florida in
2003
Michael T. Drennon
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons
This Thesis is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact scholarcommons@usf.edu.
Scholar Commons Citation
Drennon, Michael T., "Drug resistant patterns of invasive Streptococcus pneumoniae infections in the State of Florida in 2003" (2006).
Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/2509
  
Drug Resistant Patterns of Invasive Streptococcus pneumoniae 
 
Infections in the State of Florida in 2003 
 
 
 
 
by 
 
 
 
Michael T. Drennon 
 
 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science in Public Health 
Department of Epidemiology 
College of Public Health 
University of South Florida 
 
 
 
 
Major Professor: Aurora Sanchez-Anguiano, M.D. 
Roger Sanderson, M.A. 
Getachew A. Dagne, Ph.D. 
Date of Approval: 
April 4, 2006 
 
 
 
Keywords: antibiotic resistance, pneumococcal disease, risk factors, epidemiology, 
incidence 
 
© Copyright 2006, Michael T. Drennon 
i 
 
 
 
 
Table of Contents 
 
List of Tables  vi 
 
List of Figures  vii 
 
List of Acronyms and Abbreviations viii 
 
Abstract  ix 
 
Chapter One. Introduction 1 
 
Chapter Two. Background on Streptococcus pneumoniae 4 
 
 History 4 
 
 Clinical Features  4 
 
  Pneumococcal pneumonia  5 
 
  Bacteremia 5 
  Meningitis 6 
  Otitis media 6 
  Diagnosis 7 
  Treatment 7 
  Prevention 8 
   Pneumococcal Polysaccharide Vaccine 8 
   Pneumococcal Conjugate Vaccine 10 
 Epidemiology 11 
  Age 11 
  Gender 12 
ii 
  Racial and Ethnic Distributions 13 
  Geographic Distribution 14 
  Seasonality 14 
  Pre-Existing Medical Conditions 15 
 Microbiology 15 
 Serotypes 15 
 Transmission 16 
Chapter Three. Literature Review: Invasive Streptococcus pneumoniae 17 
 
 Invasive Streptococcus pneumoniae Case Definition 17 
 Florida Reporting Definition 17 
 Drug Resistant Streptococcus pneumoniae Case Definition 17 
 Drug Resistance 18 
 Methods of Testing Susceptibility 20 
  Disk Diffusion Method 20 
  E-Test 21 
  Broth Dilution Method 22 
  Susceptibility Testing 23 
  Interpretation of Test Results 24 
 Epidemiology of Drug Resistant Streptococcus pneumoniae 24 
  Geographic and Seasonal Distribution 24 
  Risk Factors 26 
   Age 26 
   Race and Ethnicity 27 
iii 
   Previous Antibiotic Use 28 
   Day Care Attendance 28 
  Studies of Incidence of Drug Resistant Streptococcus pneumoniae 29 
 Prevention and Control Measures of Drug Resistant Streptococcus  
  pneumoniae 30 
 
Chapter Four. Rationale of Study and Research Objectives 32 
 Rationale of Study 32 
 Objectives 33 
Chapter Five. Methods 34 
 Study Design 34 
 Study Population 34 
 Inclusion Criteria 35 
 Data Sources 35 
 Data Collection 35 
 Data Management 36 
 Definitions of Variables 36 
 Data Analysis 37 
Chapter Six. Results 39 
 Characteristics of the Study Population 39 
  Age  40 
  Gender 42 
  Racial and Ethnic Differences 45 
  Geographic Distribution 46 
iv 
  Seasonality 49 
 Clinically Relevant Antibiotic Resistance Patterns 52 
  Penicillin Susceptibility 52 
  Drug Susceptibility 53 
  Multi-Drug Susceptibility 55 
  Macrolides 57 
  Cephalosporins 57 
  Fluoroquinolones 58 
  Trimethoprim Sulfamethoxazole 58 
  Tetracycline 59 
  Vancomycin 59 
 Risk Factors for Antibiotic Resistance 59 
 Incidence of Streptococcus pneumoniae 63 
  Incidence by Age group 63 
  Incidence by Gender and Race 64 
Chapter Seven. Discussion 65 
 Limitations of the Study 65 
 Strengths of the Study 66 
 Interpretation of Results 67 
  Characteristics of the Study Population 67 
  Findings of Invasive Streptococcus pneumoniae 69 
  Findings of Antibiotic Resistance 70 
  Summary of Chance, Bias, and Confounding 71 
v 
 Conclusions  71 
Works Cited   73 
Appendices   78 
 Appendix A: Residual Tables and Influence Plots 79 
vi 
 
 
 
 
List of Tables 
 
Table 1.           Comparison of Age, Race, and Penicillin Resistance by  
                        percentage of population, Florida 2003 41 
 
Table 2.           Percent and Incidence of S. pneumoniae cases, Florida 2003 42 
 
Table 3.           Percentage of S. pneumoniae case per age group by gender,  
                        Florida 2003 43 
 
Table 4.           Frequency and percentage of invasive Streptococcus pneumoniae  
                        by age group, sex, and race, Florida 2003 44 
 
Table 5.           Frequency and percentage of S. pneumoniae cases by  45 
                       Ethnicity, Florida 2003 
 
Table 6.           Number of S. pneumoniae cases and incidence by county, Florida 
                        2003 46 
 
Table 7.           Reported antibiotic resistance rates of S. pneumoniae, Florida 2003 50 
 
Table 8.           Percentage and incidence (per 100,000) of Penicillin resistant 
Streptococcus pneumoniae by age group, Florida 2003 53 
 
Table 9.           Intermediate and fully resistant strains of Streptococcus  
                        pneumoniae for various antibiotics, by age group, Florida 2003 54 
 
Table 10.         Isolation of Streptococcus pneumoniae with various patterns of  
                        antibiotic resistance, Florida 2003  56 
 
Table 11.         Maximum Likelihood Estimates and Confidence Limits from  
                        logistic regression, Florida 2003 60 
 
vii 
 
 
 
 
List of Figures 
Figure 1.         Kirby Bauer Disk Diffusion: Zones of Inhibition 21 
Figure 2.         E-Test Method Compared to Disk Diffusion 22 
 
Figure 3.         Distribution of Invasive S. pneumoniae by Age Group, Florida 2003 40 
 
Figure 4.         Geographic Distribution in Counties with Populations over  
                       450,000, Florida 2003 48 
 
Figure 5.         Percentage of S. pneumoniae cases by month, Florida 2003 49 
 
Figure 6.         Incidence of S. pneumoniae by age group, Florida 2003 64 
viii 
 
 
 
 
List of Acronyms and Abbreviations 
 
ABC Active Bacterial Core Surveillance 
CDC Centers for Disease Control and Prevention 
CI Confidence interval 
CSF Cerebrospinal fluid 
CSTE Council of State and Territorial Epidemiologists 
DRSP Drug-resistant Streptococcus pneumoniae 
HIV Human immunodeficiency virus 
IPD Invasive pneumococcal disease 
MIC Minimum Inhibitory Concentration 
NCCLS National Committee for Clinical Laboratory Standards 
OR Odds Ratio 
PCV  Pneumococcal conjugate vaccine 
PPV Pneumococcal polysaccharide vaccine 
PRSP Penicillin-resistant Streptococcus pneumoniae 
RR Relative Risk 
SPIN Streptococcus pneumoniae infections in the neonate 
TMP-SMX Trimethoprim-sulfamethoxazole 
ix 
 
 
 
 
Drug Resistant Patterns of Invasive Streptococcus pneumoniae 
Infections in the State of Florida in 2003 
 
Michael T. Drennon 
 
Abstract 
 
 Streptococcus pneumoniae is a major bacterial pathogen which causes 
pneumoniae, meningitis, otitis media, and bacteremia. Currently there are two vaccines 
available, Pneumococcal Polysaccharide Vaccine (PPV) for adults and the Pneumococcal 
Conjugate Vaccine (PCV) for children. The PCV vaccine was developed in 2000 
specifically for children and infants due to the ineffectiveness of the PPV vaccine in 
children. 
 This is a cross sectional study of invasive S. pneumoniae in Florida during 2003. 
This study is designed to determine the population characteristics, clinically relevant 
antibiotic resistance patterns and specific risk factors for development of antibiotic 
resistance of invasive S. pneumoniae.  
 Participants for the study of antimicrobial resistance will be selected if they are 
positive for invasive S. pneumoniae, and have been reported to the Florida Department of 
Health, Bureau of Epidemiology with a laboratory specimen collection date in 2003. A 
total of 1056 cases were reported.  
x 
 The incidence of invasive S. pneumoniae was calculated. Logistic regression was 
used to find an association between each risk factor and invasive S. pneumoniae. 95% 
Confidence Intervals were calculated to determine statistical significance. 
 The incidence of invasive pneumococcal disease was calculated to be 6.61 per 
100,000 persons (95% CI 6.21  7.01). The incidence of drug resistant S. pneumoniae 
was calculated to be 3.3 per 100,000 persons (95% CI 3.03  3.59).The incidence of 
penicillin resistant S. pneumoniae (PRSP) was estimated to be 2.6 per 100,000 persons 
(95% CI 2.37  2.87). 
 Fifty percent of the cases qualified as Drug Resistant S. pneumoniae (DRSP), 
being non-susceptible to one or more antibiotics as defined by the National Committee 
for Clinical Laboratory Standards (NCCLS). 
 Age, race, gender, county and month of occurrence were evaluated as risk factors 
for DRSP. Only month of occurrence was determined to be a risk factor. 
 Compared to current studies and previous results for Florida, it appears that 
Florida has a decreasing incidence of antibiotic resistant Streptococcus pneumoniae. I 
believe that this is due to the use of the PCV vaccine.  
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Chapter One 
Introduction 
 
 Invasive Streptococcus pneumoniae is one of the leading causes of community-
acquired pneumonia, bacteremia and meningitis in the U.S. The rise of antibiotic 
resistance and the increased susceptibility of those with compromised immune systems 
have led to this bacteria becoming a serious public health problem. Those at highest risk 
include children less than 5 years of age, the elderly, and individuals with diseases that 
debilitate the immune system. 
 With the widespread use of antibiotics, starting in the 1940s with penicillin, there 
has been a steady rise in the number of resistant serotypes or strains of DRSP. The first 
clinical diagnosis of penicillin-resistant S. pneumoniae appeared in 1967 in New Guinea, 
and multi-drug resistant strains appeared in South Africa in 1977  (Tomasz, 1997).  
The CDC reports that annually there are an estimated 175,000 hospitalized cases 
of pneumococcal pneumonia, 50,000 cases of pneumococcal bacteremia, and 3,000-6,000 
cases of pneumococcal meningitis in the U.S. With case fatality rates as high as 30% 
among those with meningitis (CDC, 2003a). Additionally in children less than 5 years 
there are an estimated 5 million case of otitis media every year in this country. Due to the 
severity of the diseases caused by invasive S. pneumoniae and the continued rise of 
antibiotic resistance, several vaccines have been developed in the United States.  
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The first polyvalent pneumococcal vaccine was licensed in 1977, and the first 
conjugate pneumococcal vaccine for use in children was licensed in 2000 (CDC, 2003b). 
In June 1994 due to the unknown impact of DRSP the Centers for Disease Control and 
Prevention (CDC) convened a working group of public health professionals, laboratory 
experts, and physicians to devise a strategy to minimize the impact of DRSP (Jernigan, 
Cetron, & Breiman, 1996). The working groups strategy includes surveillance, research, 
prevention, and control of DRSP.  
Determining risk factors that promote development of resistance, and improving 
programs to promote pneumococcal immunization were two of the important points 
addressed by the working group (Jernigan et al., 1996).    
Another organization that monitors S. pneumoniae, The Council of State and 
Territorial Epidemiologists (CSTE) advised that all states should add DRSP to their list 
of reportable diseases in 1995. Due to this recommendation Florida added DRSP to its 
list of reportable diseases in mid 1996, as did two dozen other states. This information 
will allow for health care providers to better determine which antimicrobial therapy will 
be most effective in their community.  
It is also important to note that invasive S. pneumoniae incidence varies greatly 
throughout the world but also in the United States. According to the CDCs 
Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book 8th 
Edition), incidence of invasive pneumococcal infection in the U.S. is approximately 21 
cases per 100,000 (CDC, 2003b).  
A study by Zangwill et al. in 1996, conducted in southern California between 
March 1992 and April 1995 reported incidence rates as high as 145 per 100,000 in those 
3 
less than two years of age, with a penicillin resistance rate of 14%. In 2001 a study 
performed in Costa Rica, reported an incidence of 2.9 per 100,000 in children less then 5 
years (Ulloa-Gutierrez, Avila-Aguero, Herrera, Herrera, & Arguendas, 2003).  
The following information demonstrates the importance of researching S. 
pneumoniae in Florida. Invasive pneumococcal disease is associated with antibiotic 
resistance and a higher incidence among children less than 5 years of age, it is important 
to monitor resistance patterns and incidence among this population. Knowing the trends 
and risk factors associated with invasive pneumococcal infections will allow the 
Department of Health to develop effective strategies in reducing the incidence of this 
disease. In addition information on antibiotic resistance patterns will be made available to 
the health care community. Risk factors and antibiotic resistance patterns may aid health 
care practitioners in selecting more effective antibiotics and developing more efficient 
treatment strategies for patients. 
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Chapter Two 
Background on Streptococcus pneumoniae 
 
History 
 Streptococcus pneumoniae, also called pneumococcus, are lancet shaped, gram 
positive, anaerobic bacteria (CDC, 2003b). Pasteur first documented it in 1881, from a 
rabies patients saliva. Friedlander and Talamon made the association between the 
pneumococcus bacterium and lobar pneumonia in 1883. The discovery of the Gram stain 
in 1884 aided in distinguishing pneumococcal pneumonia from other types of pneumonia. 
There are currently 90 known serotypes, with the ten most common causing greater than 
60% of worldwide invasive disease (CDC, 2003a). 
 
Clinical Features 
 Streptococcus pneumoniae is one of the leading causes of pneumonia, meningitis, 
bacteremia, and otitis media. Additionally it can cause conjunctivitis, sepsis, sinusitis, 
and other diseases. Streptococci commonly inhabit the nasopharyngeal tract of humans, 
and can easily spread to other sites in the upper-respiratory tract to cause infection 
(Keyworth, 2000). In the case of infection of the central nervous system (CNS), heart 
valves, and joints, the circulatory system is the main means of transmission (Mandell, 
Bennett, & Dolin, 2000). In most cases of infection a predisposing condition exists, 
usually some pulmonary disease.   
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Pneumococcal pneumonia 
 Pneumococcal pneumonia is the most common form of pneumococcal infection in 
adults, and accounts for approximately 36% of community-acquired pneumonia and 50% 
of hospital-acquired pneumonia. The period of time from infection to presentation of 
signs and symptoms is short, lasting only one to three days. Mortality rates range from 5-
7%, and may be higher in the elderly (CDC, 2003b).  
Patients usually present with sudden symptoms which include high fever, shaking 
chills, and a productive cough. Additional symptoms can include dyspnea, tachypnea, 
hypoxia, tachycardia, malaise, and weakness. The patients sputum will tend to have a 
rusty hue and may be abundant (Lashley & Durhan, 2000).  In most cases there is a 
predisposing factor, which can include pulmonary disease, alcoholism, renal disease, and 
several other conditions (Mandell et al., 2000). Children can present with nausea, 
vomiting, and diarrhea, which are less common in adults. Elderly patients, those over 65 
years old, may not show signs of a fever, cough, or increased sputum but tend to have a 
higher incidence of mental disorientation (Lashley & Durhan, 2000).  
 
Bacteremia 
 Pneumococcal bacteremia accounts for more than 50,000 cases of invasive 
pneumococcal infection each year in the United States. The average mortality rate is 20% 
but in the elderly population can be as high as 60%. As with other forms of 
pneumococcal infection rates are higher in children, the elderly and other groups of 
immuno compromised individuals. Bacteremia is the most common from of invasive 
pneumococcal infection in children under the age of 2 years, constituting up to 70% of all 
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invasive pneumococcal infection in this age group (CDC, 2003b). Bacteremia frequently 
occurs in patients already suffering from pneumonia or meningitis. Patients usually 
present with temperature extremes (fever or hypothermia), tachycardia, tachypnea, 
hypotension and can be disoriented (Lashley & Durhan, 2000).  
 
Meningitis 
 There are an estimated 3,000 to 6,000 cases of pneumococcal meningitis each 
year in the United States, which accounts for approximately 19% of all cases of bacterial 
meningitis in the U.S. Approximately 25% of patients with pneumococcal meningitis 
already have pneumoniae. Case-fatality rates are approximately 30% but can be has high 
as 80% in elderly person (CDC, 2003b).  
 The patient may present with headache, lethargy, vomiting, fever, seizures, and 
coma. Correct diagnosis is confirmed after the examination of a Gram-stained spinal fluid 
specimen (Mandell et al., 2000).  
 
Otitis Media 
 Of all pneumococcal infections, otitis media by far accounts for the most hospital 
visits associated with this bacterium. Each year in the U.S. there are approximately 20 
million hospital visits for otitis media, of that 5 million occur in children less than 5 years 
old (CDC, 2003b).  
 The patient will present with fever and ear pain (Lashley & Durhan, 2000). 
Congestion of the eustachian tube caused by a prior viral respiratory infection is thought 
to be a significant factor in the development of otitis media (Mandell et al., 2000). This 
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congestion of the eustachian tube allows for the colonization of S. pneumoniae, which 
can lead to infection.  
 
Diagnosis 
 To definitively diagnose a S. pneumoniae infection the microorganism must be 
isolated from a sterile sample of body fluid (e.g. blood, spinal fluid). A gram stain will 
reveal Gram-positive, lancet shaped diplococci. Sputum is not considered a high-quality 
source, due to the normal nasopharyngeal bacteria. The quelling reaction test is used for 
rapid identification of pneumococci. Another test used to detect pneumococcal capsular 
polysaccharide antigen is Counterimmunoelectrophoresis (CIE), this method is both rapid 
and specific (CDC, 2003b).  
 
Treatment 
 The general principles of treating a pneumococcal infection are similar to treating 
any other infection. First administer an antibiotic at a level adequate enough to inhibit or 
kill the bacteria. Second, continue treatment for an adequate period of time. Third, drain 
infection from closed spaces if necessary. Fourth, follow up and know what results to 
expect. Finally, be ready to re-evaluate treatment if observed response is not what is 
expected or treatment is not working (Mandell et al., 2000). There are several issues that 
arise in the treatment of S. pneumoniae that can complicate treatment. For most cases 
caused by pneumococcus, at the time of treatment the causative organism is unknown. In 
the cases where S. pneumoniae is considered the causative organism, antibiotic 
susceptibility is not known at the start of treatment. The duration of treatment necessary 
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to kill the bacteria is not known for most common cases of S. pneumoniae infections. In 
the cases where S. pneumoniae presents as otitis media or sinusitis, drainage is not 
usually done. In cases involving pneumococcal infections, physicians are not sure what to 
expect once the treatment has begun (Mandell et al., 2000). 
 
Prevention 
 Developing an effective prevention strategy would be a valuable tool in reducing 
the burden of this disease on the population and the financial cost associated with the 
disease. In addition to decreasing the number of infections it would also reduce problems 
associated with the development of new drug-resistant strains of the bacterium.  
 The first pneumococcal vaccine was developed in the 1940s, but use was 
discontinued with the development of successful antimicrobial therapy (Lashley & 
Durhan, 2000). Currently there are two vaccines available, Pneumococcal Polysaccharide 
Vaccine (PPV) for adults and the Pneumococcal Conjugate Vaccine (PCV) for children. 
The PCV vaccine was developed in 2000 specifically for children and infants due to the 
ineffectiveness of the PPV vaccine in children.  
 
Pneumococcal Polysaccharide Vaccine. The pneumococcal polysaccharide vaccine is 
composed of purified pneumococcal capsular polysaccharide. The first vaccine of this 
type was developed and licensed in 1977 for use in the United States; it contained 14 
serotypes of the pneumococcal bacteria. In 1983 a second vaccine was licensed that 
contained 23 serotypes, the 23-valent polysaccharide vaccine (PPV23) contained the 
serotypes that account for 88% of pneumococcal disease in the U.S (CDC, 2003b).  
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 The vaccine works by generating a serotype specific response by antibodies, that 
increases recognition, attachment and killing of pneumococci by leukocytes (Lashley & 
Durhan, 2000). A high percentage of adults (90-95%) receiving the vaccine produce 
antibodies to 75% of the serotypes in the vaccine. The pneumococcal vaccine is thought 
to be protective for up to five years in healthy individuals, but at a diminishing rate 
(Mandell et al., 2000). The vaccine is 60-70% effective in preventing all pneumococcal 
disease, but is not as effective in preventing pneumococcal pneumoniae. Effectiveness 
also diminishes in high risk groups, predominantly those with an underlying medical 
condition.  
 Currently there are two polysaccharide vaccines available in the U.S. Pneumovax 
23 developed by Merck, and Pnu-Immune 23 by Lederle, both vaccines are very similar. 
The vaccine is administered by injection, either intramuscularly or subcutaneously (CDC, 
2003b).  
 It is recommended that all adults over the age of 65 should receive the vaccine on 
a routine basis. Individuals who have a suppressed immune system and are over two 
years old are also recommended to receive the vaccine, if they are at a particular high risk 
to contract a pneumococcal infection. Revaccination is recommended five years after the 
first injection for individuals who are at high risk for developing a pneumococcal 
infection. Revaccination is not recommended for immuno-competent persons (CDC, 
2003b).  
 
Pneumococcal Conjugate Vaccine. Due to the ineffectiveness of PPV-23 in children less 
than 6 years old, a new vaccine was developed. In February of 2000 the first 
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pneumococcal conjugate vaccine (PCV7) was licensed in the United States. The vaccine 
contains capsular polysaccharide from 7 S. pneumoniae serotypes. The serotypes are 
conjugated to a nontoxic diphtheria toxin. The vaccine induces a higher antibody count 
and primed B-cells. These seven serotypes account for 86% of bacteremia, 83% of 
meningitis, and 65% of acute otitis media in U.S. children 6 years old and younger. The 
vaccine is administered intramuscularly (CDC, 2003b).  
 One cause of concern is that this vaccine only covers a few serotypes; pressing the 
question will additional vaccines covering different serotypes or more serotypes increase 
the effectiveness of the conjugated vaccine. Currently vaccines containing 9 and 11 
serotypes are being developed and evaluated (CDC, 2003b).  
 After the four recommended doses, almost all healthy infants acquire antibodies 
to all 7 of the serotypes. This vaccine has been shown to reduce pneumococcal disease 
caused by the 7 serotypes by 97%, and reduce disease caused by serotypes not in the 
vaccine by 89%. The vaccine is less effective in preventing pneumonia and acute otitis 
media (CDC, 2003b). 
 Children less than 24 months old and children between the ages of 2 and 5 years 
who suffer from compromising medical conditions should receive this vaccine. Four 
doses are recommended by the CDC at 2, 4, and 6 months of age and then a booster at 
12-15 months old. Children who are not vaccinated by 7 months require fewer doses, 
depending on their age. Re-vaccination is not recommended after the initial series (CDC, 
2003b). 
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Epidemiology 
 Invasive Streptococcus pneumoniae occurs throughout the world with the highest 
incidence in the elderly, young children, and individuals with an immuno compromising 
condition. Due to the severity of the diseases associated with this bacterium, it is a major 
cause of morbidity and mortality worldwide. The burden of disease is also significant in 
the U.S., with high mortality rates often associated with those of compromised status 
(CDC, 2003b).  
 
Age 
 Over all incidence in the U.S. for invasive Streptococcus pneumoniae was 
approximately 21 cases per 100,000 persons in 2002, with the disease rate decreasing due 
to the introduction of the conjugate vaccine (CDC, 2003c). Prior to the introduction of a 
vaccine the incidence was approximately 700 per 100,000 in the young adult population 
(Mandell et al., 2000).  
 Age is a significant risk factor for Streptococcus pneumoniae infection, 
considering the large discrepancies among age groups. A current study by Whiney et al., 
in 2003 found the following incidence rates: 17.3 per 100,000 overall, incidence rates for 
children less than 2 years of age was 59 per 100,000, and incidence in the adult 
population and those over 65 years of age was 7.6 and 49.5 per 100,000 persons 
respectively.  
A study in the U.S. reported that of 15,860 cases, approximately 30% occurred in 
those over the age of 65 years, and 20% from children less than 2 years of age (Robinson, 
Baughman, Rothrock, Barrett, Pass et al., 2001).  A hospital-based study in Catalonia, 
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Spain reported an incidence rate of 59.6 per 100,000 person years for children less than 2 
years of age and 27.9 per 100,000 person years in persons greater than 65 years. The total 
incidence reported was 10.5 per 100,000 person years (Dominguez, Salleras, Cardenosa, 
Ciruela, Carmona et al., 2002). From these studies we can see that the two age groups 
most affected are persons less than 2 years of age and persons greater than 65 years of 
age.  
 Streptococcus pneumoniae infections in the neonate (SPIN) are of particular 
concern because Pneumococcal Conjugate Vaccine (PCV) is not administrable to infants 
less than 2 months old. Infections like sepsis, pneumonia and meningitis occur with low 
frequency in this age group, mortality associated with the infections is high. A study in 
the U.S. examining SPIN found that infants usually presented at 2 to 3 weeks of age with 
pneumonia, meningitis, or otitis media. This late onset was associated with a mortality 
rate of 14.3% in invasive infections (Hoffman, Mason, Schutze, Tan, Barson et al., 2003). 
 
Gender 
 A study conducted in Southern California found that rates among males and 
females were very similar, with males (13.3 per 100,000) having a slightly higher 
incidence than females (11.9 per 100,000) (Zangwill, Vadheim, Vannier, Hemenway, 
Greenberg et al., 1996). In Austria, a recent prospective surveillance found that in 
hospitalized children less than 5 years old males accounted for twice as many invasive 
pneumococcal disease (IPD) infections as females (Rendi-Wagner, Georgopoulos, Kundi, 
Mutz, Mattauch et al., 2004).  A study from South Africa recently reported that compared 
to men, women are more likely to be infected with a pediatric serotype (OR 1.59, 95% CI 
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1.18-2.15), and have a penicillin-nonsusceptible strain (OR 1.65, 95% CI 1.03-2.59) 
(Buie, Klugman, Gottberg, Perovic, Karstaedt et al., 2004).  
 
Racial and Ethnic Distributions 
 Some studies have shown that prior to 2000 and the introduction of a conjugated 
vaccine, incidence of pneumococcal infection was higher in black Americans. A 
population based study conducted in Dallas County, Texas in 1995 reported incidence 
among black non-Hispanic to be 39 per 100,000 person years and 18 per 100,000 person 
years in whites. This study also reported that rates among Hispanics were similar to those 
in the white population (Pastor, Medley, & Murphy, 1998). A study examining the 
disease burden in the United States found that in 1998 incidence in the black population 
was 2.6 times that of the white population (Robinson et al., 2001). A study of racial 
differences in pneumococcal disease in Tennessee reported that in 1999 the rate of 
invasive pneumococcal disease in black children under 2 years of age was 340 per 
100,000 persons, but in 2002 this rate had dropped 83% (Talbot, Poehling, Hartert, 
Arbogast, Halasa et al., 2004).  
 American Indians have also been shown to be at greater risk for invasive 
pneumococcal infections. The rate of invasive pneumococcal disease (IPD) in Navajo 
children less than 2 years old was 537 per 100,000 persons, between 1989 and 1996 
(O'Brien, Moulton, Ried, Weatherholtz, Oski et al., 2003).  Navajo adults are also at 
greater risk for IPD, with reported rates 2-3 times higher than those of the general 
American population (Benin, O'Brien, Watt, Ried, Zell et al., 2003). 
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Geographic Distributions 
 Streptococcus pneumoniae occurs worldwide. Annually, worldwide more than 
one million children less than 5 years old die of an invasive disease caused by S. 
pneumoniae (Bogaert, de Groot, & Hermans, 2004). The CDC reports that in the U.S. 
IPD contributes to more than 40,000 deaths each year (Lashley & Durhan, 2000). 
Incidence rates vary from country to country, and can even differ widely in countries that 
are adjacent to each other.  
 
Seasonality 
 Similar to other infectious diseases, incidences of invasive pneumococcal 
infections change in a seasonal pattern. Evidence shows that there is a steady increase in 
the fall months, and a spike in midwinter (Dowell, Whitney, Wright, Rose, & Schuchat, 
2003). Another study reported a distinct association between decreased ambient air 
temperature and an increase in pneumococcal infections (Kim, Musher, Glezen, 
Rodriguez-Barradas, Nahm et al., 1996). 
 
Pre-existing Medical Conditions 
 Medical conditions that suppress the immune system greatly increase an 
individuals potential for pneumococcal infection: multiple myeloma, chronic 
lymphocytic leukemia, lymphoma, HIV infection, aplastic anemia, sickle cell disease, 
and any form of organ transplantation. A study conducted in 1996 in Southern California 
concluded that individuals with HIV (incidence: 176 per 100,000 persons) were at a 
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significantly greater risk than individuals in the general population (incidence: 12.5 per 
100,000 persons) (Zangwill et al., 1996).  
 
Microbiology 
 Streptococcus pneumonia is a gram-positive, catalase negative diplococcus which 
replicates in chains in liquid medium. Pneumococci produce alpha-hemolysin; this 
substance breaks down hemoglobin producing a green color. When grown on a blood 
agar plate, pneumococci are encircled in a green zone, this is indicative of a positive test. 
Additionally pneumococci can be identified using two other tests: catalase negativity, and 
solubility in bile salts or ethyl hidrocupreine (optochin) susceptibility.  This last method 
has been shown to not be as effective due to increased resistance to optochin, 
microbiologists rely more on the bile salt test (Mandell et al., 2000).  
 
Serotypes 
 Streptococcus pneumoniae is normally surrounded by an external polysaccharide 
capsule, only in rare cases has the infection been due to a non-encapsulated form of the 
bacterium (Mandell et al., 2000). There are currently 90 known serotypes of S. 
pneumoniae, which are differentiated by the type of antigens on the cell capsule (Lashley 
& Durhan, 2000).  During the 1930s serotyping was clinically relevant due to the fact that 
antisera were administered as therapy; this is no longer standard practice. Currently 
serotyping is mainly used for research purposes (Mandell et al., 2000). 
There are two numbering methods used: the American and Danish systems. The 
American system numbers serotypes 1 to 90 in order of identification. Since strains that 
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frequently cause human infection were identified first and thus numbered first, explains 
why lowered number serotypes are often the cause of IPD. The Danish system is based 
on antigen similarities; group 19 includes 19F, 19A, 19B, and 19C. In the American 
system these serotypes would be 19, 58, 57, and 59 respectively (Mandell et al., 2000). 
The Danish method is the more commonly used system. 
The majority of the 90 serotypes are known to cause infection, however 62% of 
invasive disease around the world is caused by only the 10 most common serotypes. The 
serotypes linked to disease are dependent upon age group, in the United States 7 
serotypes (4, 9V, 14, 19F, 23F, 18C, and 6B) account for 80% of infections in children 
less than 6 years of age. These same serotypes account for approximately 50% of the 
infection in older children and adults (CDC, 2003b).  
 
Transmission 
 S. pneumoniae is a human pathogen. There is no animal to human vector. Similar 
too many other microorganisms pneumococci colonize the nasopharynx of 
asymptomatic human carriers. S. pneumoniae is carried in about 40% of healthy adults 
and carriage rates in children are even higher (Lashley & Durhan, 2000).  
Transmission occurs secondary to direct person to person contact, by means of 
respiratory droplets. Transmission can also occur through direct oral contact and items 
freshly soiled with respiratory droplets (Chin, 2000). Within a household, factors such as 
crowding, season, upper respiratory infections, or pneumococcal infection can increase 
the potential for transmission. It should be noted that presence of these factors does not 
necessarily increase the risk of transmission within the home (CDC, 2003b).
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Chapter Three 
Literature Review: Invasive Streptococcus pneumoniae 
 
 
Invasive Streptococcus pneumoniae Case Definition 
 Active Bacterial Core Surveillance defines a case of invasive pneumococcal 
disease as isolation of S. pneumoniae from a sterile source such as blood or cerebrospinal 
fluid (CSF). A case is defined as meningitis if S. pneumoniae is isolated from CSF, or if 
there is a clinical diagnosis and the bacterium is isolated from blood (Robinson et al., 
2001).  
 
Florida Reporting Definition 
According to the Florida Department of Health Bureau of Epidemiology, 
diagnosis is confirmed when S. pneumoniae is isolated from a normally sterile site (e.g. 
blood, CSF). Case information is collected by county health departments and is sent to 
the Bureau of Epidemiology involving all invasive S. pneumoniae cases (Florida 
Department of Health, 2000). 
 
Drug Resistant Streptococcus pneumoniae (DRSP) Case Definition 
 S. pneumoniae is considered resistant if the bacterium is resistant to one or more 
commonly used antibiotics. Antibiotic resistance and susceptibility is determined by 
antibiotic Minimum Inhibitory Concentration (MIC) breakpoints. Breakpoints for 
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resistance and susceptibility vary by antibiotic. Breakpoints for MIC counts are 
determined by NCCLS.  
 
Drug Resistance 
 With the steady rise of antimicrobial resistance among strains of S. pneumoniae in 
the past decade it is now more important than ever for physicians to prescribe proper 
antimicrobial therapy. Where penicillin was previously the drug of choice for all 
pneumococcal infections, there are now areas within the U.S. that report 30% of all 
strains are resistant to penicillin. An additional area of concern is strains of S. 
pneumoniae that are multi-drug resistant, leading to problems with treatment.  
Multi-drug resistance is defined as a strain being resistant to two or more 
antibiotics. Some of these multi-drug resistant strains are only susceptible to vancomycin. 
Antibiotics that were unnecessarily prescribed plays a large factor in the development of 
DRSP (CDC, 1996). 
 A recent 3-year study conducted in Quebec examined serotype distribution, 
antimicrobial susceptibility, and clinical characteristics. The findings showed that over all 
the incidence rates remained stable over the three year period, but there was a significant 
rise in nonsusceptible isolates in young children from 7.9 to 25.3%. Additionally multiple 
resistance was reported in 4.1% of the isolates, these isolates were resistant to β-lactams 
and at least two of the following antimicrobials: erythromycin, chloramphenicol, 
trimethoprim-sulfamethoxazole (TMP-SMX), and ofloxacin (Jette, G., Ringuette, Allard, 
De Wals et al., 2001).  
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 Chenoweth et al., in 2000 conducted a review of literature on antimicrobial 
resistance in patients with community-acquired pneumonia. They reported that in the 
United States, since 1991 penicillin resistance has increased substantially, from a high of 
5% (intermediate and full resistance) in 1991 to 43.8% (intermediate and full resistance) 
reported in 1998. Pneumococci that were resistant to penicillin were also reported to be 
resistant to 1st and 2nd generation cephalosporins, while 3rd generation cephalosporins 
(cefotaxime and cefrtiaxone) continued to be somewhat effective. Carbapenems were 
found to still be an effective antimicrobial in treating penicillin resistant strains of S. 
pneumoniae. Macrolide (erythromycin) resistance is reported to be between 11-14% for 
intermediate resistance and up to 7% in highly resistant strains. Strains that are resistant 
to erythromycin are commonly resistant to azithromycin. TMP-SMX resistance is 
increasing similarly to that of penicillin, with resistance to both often occurring in the 
same isolate. Vancomycin is the only antibiotic S. pneumonia has not yet formed a 
resistance to.  
 Considering that vancomycin is one of the last lines of defense in antimicrobial 
therapy for DRSP, it is important to monitor for any new developments in resistance. A 
recent study performed in Colombia, South America examined tolerance to vancomycin 
in 7 isolates of serotype 14. Tolerance is defined as the ability to inhibit growth but not 
completely kill the pathogen. The study found that one isolate had phenotypical 
characteristics of tolerance to vancomycin. This isolate showed high resistance to 
penicillin as well as other antibiotics (Hidalgo, Castaneda, & Arias, 2003). While 
tolerance occurred in only a small number of isolates, this is still a significant finding. 
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Methods of Testing Susceptibility 
 Methods for antimicrobial susceptibility testing of Streptococcus pneumoniae are 
determined by the NCCLS. There are several methods used to test for antimicrobial 
susceptibility in Streptococcus pneumoniae; the three most common are the Disk 
Diffusion method, the E-Test, and the Broth Dilution method.  
 
Disk Diffusion Method 
 This method is also known as the Kirby Bauer diffusion method. This is one of 
the more common methods used in determining antimicrobial susceptibilities. In this 
method, small paper disks, 6mm in size, are infused with a standard amount of antibiotic 
and placed on an agar plate that has been inoculated with S. pneumoniae. NCCLS 
suggests that Mueller-Hinton agar containing 5% sheep blood, incubated at 35 oC; 5% 
CO2; for 20 to 24 hours be used to grow S. pneumoniae. For screening methods a disk 
infused with 1µg of Oxacillin to determine penicillin resistance, but does not determine 
quantitative susceptibility (Kiska, Kerr, Jones, Chazotte, Eskridge et al., 1995). Zone size 
and specific antibiotic content per disk is determined by NCCLS. A large zone of 
inhibited growth is indicative of susceptible (S) strain of the bacteria, inhibited growth 
that falls between the breakpoints for susceptible and resistant is deemed to be 
intermediate (I), and if the growth zone  is less than the breakpoint then it qualifies as 
resistant (R). (Figure 1).  
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                                          Figure 1: Kirby Bauer Disk Diffusion: Zones of Inhibition 
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                                          Source: (Sachais, 1997) 
 
E-Test 
 The E-Test method, manufactured by AB biodisk (Culver City, Calif.), is similar 
to the disk diffusion method in that a plastic strip is infused with the antibiotic. This strip 
in addition has a gradient that allows for precise and accurate reading of the results. 
(Figure 2) The manufactures recommendations for growth of S. pneumoniae are the 
same as NCCLS for the disk diffusion method. NCCLS also determines the breakpoints 
for the E-Test method. The strip is read where the inhibited growth intersects the E Test 
strip. The E-Test strip is marked in one half log2 increments. One study notes that it is 
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important to take care and read where pneumococcal growth stops and not the area of 
alpha-hemolysis (Jorgensen, Ferraro, McElmeel, Spargo, Swenson et al., 1994). 
 
                 Figure 2: E-Test Method compared to Disk Diffusion 
 
                Source: (Facklam, 2003) 
 
                  
 
Broth Dilution Method 
 NCCLS recommends using cation-adjusted Mueller-Hinton broth, supplemented 
with 5% lysed horse blood for pneumococci. S. pneumoniae that will be used to inoculate 
the microdilution trays is grown on sheep blood agar plates for 24 hours in 5% CO2. A 
final inoculum density of 5 x 105 CFU/ml is placed in the microdilution wells and 
incubated for 20-24 hours at 35 oC in ambient air (Jorgensen et al., 1994). 
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Susceptibility Testing 
 In February 2000 the CDC reported the results of a survey used to determine 
susceptibility testing practices for S. pneumoniae in the United States. The survey was 
used to determine: which susceptibility tests were used, whether laboratories were 
following NCCLS guidelines, which antimicrobials were being tested, and how results 
were being reported to clinicians. The laboratories were chosen by their participation in 
the CDCs Emerging Infections Program, Active Bacterial Core Surveillance (ABC). Of 
the 659 labs questioned most were using proper NCCLS methods. The results showed 
that the majority of laboratories used the E-Test for penicillin, the disk diffusion method 
for Fluoroquinolones, and broth microdilution for other antimicrobials. The majority of 
laboratories reported the results of the test to clinicians as an interpretation (i.e. 
susceptible, intermediate, or resistant). Additionally most laboratories (70%) reported the 
minimum inhibitory concentration (MICs) to the clinician, while only 5% reported the 
zone diameter (Gelling, Rothrock, Vugia, Shillam, Burnite et al., 2002).  
 With the increase in incidence of multi-antibiotic resistance and the increase in 
penicillin resistance among S. pneumoniae strains there have been several studies done to 
evaluate tests that are both accurate and quick. Macias et al., in 1994 compared the 
effectiveness of the E-Test against the standard broth microdilution method in 
determining penicillin resistant strains of S. pneumoniae. The results found that while the 
E-Test is a reliable method there are some issues; a difference in the dilution schemes of 
the two tests, and E-Test results are on a linear scale and not directly comparable to 
results from the dilution method. 
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Interpretation of Test Results 
 Results for the above tests are determined by NCCLS zone diameter and MIC 
breakpoints for each antibiotic. Each year the susceptibility breakpoints are reviewed and 
updated if necessary. In January of 2003 NCCLS updated the breakpoints of S. 
pneumoniae for cefotaxime and cefrtiaxone; these new breakpoints were made to 
differentiate between strains causing meningitis and nonmeningeal diseases. MIC 
breakpoints for penicillin were not changed because penicillin breakpoints are also used 
to predict resistance in other penicillins, cephalosporins, and carbapenems (Daily, Farley, 
Jorgensen, Barrett, Thompson et al., 2004). 
 
Epidemiology of Drug Resistant Streptococcus pneumoniae 
 Due to the rise of antibiotic resistance among isolates of S. pneumonia and the 
severity of the diseases it causes largely contribute to the importance of monitoring the 
resistance patterns and risk factors for DRSP. It is important to determine trends and risk 
factors of the disease to aid health care workers in developing effective strategies in 
combating S. pneumoniae.  Geographic and seasonal trends are important to monitor to 
keep track of when and where disease occurs. Risk factors include but are not limited to; 
age, race, previous antibiotic use, day care attendance, and recent hospitalization.  
 
Geographic and Seasonal Distribution 
 Streptococcus pneumoniae occurs world wide, with a varying incidence rates not 
only in other countries but within the United States as well. The following studies 
illustrate varying rates throughout the world. An epidemiologic study in Southern 
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California evaluating the effectiveness of PCV, reported incidence rates of 145/100,000 
in children less than 2 years old, 72/100,000 in children less than 5 years old and 
32/100,000 in adults over the age of 65. At the same time there was no increase in 
penicillin resistance, however there was an increase in high-level resistance from 4% to 
21% (Zangwill et al., 1996). Massachusetts children less than 7 years old presenting for 
routine well visits were tested for pneumococcal colonization, 26% were found to be 
colonized with S. pneumoniae. One hundred and sixty-six of the isolates were tested for 
susceptibility, 33% were found to be susceptible to penicillin, 14% resistant to 
cephalosporins, and 22% resistant to erythromycin (Finkelstein, Huang, Daniel, Rifas-
Shiman, Kleinman et al., 2003).  
 Incidence rates for children less than 2 years old in Austria were 14.5/100,000 and 
an overall incidence rate of 13.7/100,000 persons. 21.4% of S. pneumoniae isolates 
showed intermediate resistance, while none were found to have full resistance. 32.1% of 
the isolates had developed full resistance to clarithromycin, and 33.9% had developed 
resistance to erythromycin (Rendi-Wagner et al., 2004).  
Very low rates of penicillin resistance (2.6% of isolates) have been reported in 
children less than 2 years old in Tasmania Australia, additionally no high resistance 
found to 3rd generation cephalosporins (Christie, Coleman, Wan, Jacobs, & Carapetis, 
2002). 
A recent study in Switzerland had the most striking geographic difference; an 
outbreak of a specific strain of S. pneumoniae caused a large increase in prevalence (6.8 
to 19.7%) in the west region of the country. While the east region of Switzerland had a 
slight decrease in prevalence of 7.7 to 5.2%. Penicillin susceptibility was 90% for those 
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less than 17 years old, and 81% for children less than 2 years (Muhlemann, Matter, 
Tauber, & Bodmer, 2003). These susceptibly numbers are slightly higher than those of 
other studies, indicating that resistance is not yet a significant problem in Switzerland. 
 Seasonal studies have shown that there is an increase in pneumococcal infections 
each winter. Dowell et al., in 2003 reported that there is a distinct fall increase in 
pneumococcal infection and a midwinter peak. These patterns are consistent across seven 
U.S. geographical regions. The study also reported that there was no distinct temperature 
pattern associated with disease. The seasonal peak between children and adults differed, 
while the adults displayed a distinct peak in mid-winter children displayed a broader and 
flatter peak. Additional studies have also shown this midwinter peak in pneumococcal 
disease. These studies have also reported a significant association between respiratory 
viruses and SO2 levels, and an increase in pneumococcal infections (Kim et al., 1996). 
 
Risk Factors 
Age. Young children and adults over the age of 65 have been shown to be at a greater risk 
of developing a pneumococcal infection. These two age groups are at a higher risk 
because their immune systems are more susceptible.  
 A hospital based study in Catalonia, Spain evaluating incidence rates of S. 
pneumoniae over a three year period (January 1997-December 1999) reported 1218 
pneumonias positive for S. pneumoniae. Of these case 6.8% were in children less than 2 
years, and 45.7% in adults over 65 years (Dominguez et al., 2002). 
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 Decreased susceptibility to penicillin was found in 37% of S. pneumoniae 
isolates obtained during an 8-year study of children less than 5 years old in Uruguay, 
South America (Camou, Palacio, Di Fabio, & Hortal, 2003). 
 A Brazilian prevalence study examining S. pneumoniae resistance to penicillin in 
a hospital from July 1991 to December 1992 and 1994, found that 21.8% of isolates had 
intermediate resistance to penicillin. The study also reported that being less than 4 years 
old (OR 3.53, 95% CI: 1.39-8.96) was associated with decreased susceptibility (Levin, 
Sessegolo, Teixeira, & Barone, 2003). 
 A 1995 Dallas county, Texas study of invasive pneumococcal disease found that 
the highest incidence of IPD occurred in children less than 2 years old (136/100,000 
person years) and adults over 65 years (80/100,000 person years). Twenty percent of the 
isolates were reported to be non susceptible to penicillin, with resistance rates higher in 
individuals <2 years and >65 than in those 2-29 or 30-64 years old (Pastor et al., 1998). 
 
Race and Ethnicity. Studies have shown white race is associated with DRSP. In 
Baltimore, MD white individuals were found to account for the majority of penicillin 
resistant S. pneumoniae (PRSP) infections. The authors note that the incidence of PRSP, 
which is a product of the incidence of pneumococcal infection and the proportion of 
disease due to PRSP, was higher among black individuals (Albanese, Roche, Pass, 
Whitney, McEllistrem et al., 2002).  
 A 1995 Atlanta study found that while incidence of invasive pneumococcal 
infection was higher in blacks, whites were actually at a higher risk of DRSP (Risk Ratio 
1.66). The authors state that better access to health care and abuse of antibiotics among 
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whites, probably contributes to the higher risk among that population (Hofmann, Cetron, 
Farley, Baughman, Facklam et al., 1995).  
 
Previous Antibiotic Use. Previous antibiotic use has been shown to be one of the primary 
risk factors in contributing to antimicrobial resistance in pneumococci (Chenoweth, Saint, 
Martinez, Lynch III, & Fendrick, 2000). The increase use in Fluoroquinolones and 
several other drugs has led to the increase in mutations among S. pneumoniae strains 
resulting in resistance (Goldstein & Garabedian-Ruffalo, 2002). In rural Kentucky 
previous antibiotic treatment was found to be independently predictive (P<0.0001) of 
PRSP, in patients with acute otitis media (AOM) (Block, Harrison, Hendrick, Tyler, 
Smith et al., 1995). 
 A 1998-1999 Switzerland study using nationwide surveillance data, ran analysis 
on 1179 pediatric (<17 years) pneumococcal isolates to determine risk factors for 
pneumococcal infection. This study found, using logistic regression, that age and recent 
antibiotic therapy were risk factors for carriage of penicillin non-susceptible S. 
pneumoniae (PNSP) (Muhlemann et al., 2003).  
 
Day Care Attendance. A Massachusetts study conducted in 2001 reported day care 
attendance as an independent risk factor (OR: 3.9)  for PNSP (Finkelstein et al., 2003). 
Recent day care attendance was determined to be a risk factor (OR 3.79) in children 
between 2-59 months, in North America (Levine, Farley, Harrison, Lefkowitz, McGeer et 
al., 1999). 
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 Younger siblings of day-care attendees are at an increased risk of exposure to 
DRSP. Givon-Lavi et al. found that carriage of S. pneumoniae and antibiotic resistance 
was high among both day-care attendees and their younger siblings. Strains that are 
included in the 7-valent vaccine, and are associated with antibiotic resistance, were 
significantly higher in the younger siblings (Givon-Lavi, Fraser, Porat, & Dagan, 2002).  
 
Studies of Incidence of DRSP 
 Several studies, examining S. pneumoniae incidence and drug resistance strains of 
the bacteria, have been conducted not only in the U. S. but in other countries throughout 
the world. A number of those studies are summarized here, to further emphasize the 
importance of this growing problem.  
 A 1994 Atlanta based study found an overall incidence rate of invasive disease to 
be 30 cases per 100,000 persons. Penicillin-resistant rates were 6/100,000 for whites and 
11/100,000 among blacks. Penicillin resistance occurred in 25% of the isolates. Penicillin 
often coincided with other antibiotics in multi-resistant strains. Young children were 
found to be at a higher risk of DRSP infection compared to older patients (6% vs. 2%, 
RR of 2.27, 95% CI: 0.84-6.14). Penicillin resistance was reported to be a greater issue 
among whites than blacks (32% vs. 19%, RR 1.66, 95% CI: 1.18-2.32) (Hofmann et al., 
1995). 
 From July 1998 to August 1999, meropenem efficacy was evaluated in a tertiary 
childrens hospital in the southern United States. The study found that pneumococci that 
have high resistance to penicillin and cefotaxime also had high resistance to meropenem. 
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Twenty-seven of 29 penicillin resistant strains were also resistant to meropenem 
(Buckingham, Davis, & English, 2002). 
 An 11 year study in Barcelona, Spain examining incidence among children found 
that 37.1% of the isolates had intermediate resistance to penicillin and 8.6% demonstrated 
high resistance. Additionally 32.4% of the isolates were resistant to erythromycin 
(Pineda, Fontanals, Larramona, Domingo, Anton et al., 2002).  
 Trimethoprim-sulphamethoxazole (TMP-SMZ) is a common antibiotic used in 
HIV/AIDS patients, to prevent infection with Pneumocystis carinii. Several studies have 
been conducted throughout the world to determine if long-term use increases risk of 
infection with TMP-SMZ resistant strains of bacteria.  
 Using ABCs data from 1998-1999 Fry et al., in 2003 concluded that long term 
therapy with TMP-SMZ does not increase an HIV/AIDS patients chance of becoming 
infected with a TMP-SMZ resistant strain of S. pneumoniae. A study in Zimbabwe also 
concluded that HIV status did not increase a persons risk of DRSP, but did report that 
50% of isolates were resistant to TMP-SMZ among HIV positive individuals. This study 
also reported that penicillin resistance occurred in 50% of strains in HIV seropositive 
individuals, compared to only 16% of isolates in HIV seronegative patients (Gwanzura, 
Pasi, Nathoo, Hakim, Gangiadzo et al., 2003). 
 
Prevention and Control Measures of DRSP 
 Cost associated with the diseases caused by DRSP is an important factor to take 
into consideration when discussing prevention and control. Cost of treatment for adults 
has been found to be higher among patients with an S. pneumoniae infection resistant to 
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penicillin as opposed to a susceptible strain. The increased cost is associated with a 
longer length of stay and more expensive antibiotic, cefrtiaxone versus penicillin G 
(Quach, Weiss, Moore, Rubin, McGeer et al., 2002).  
 An Austrian study conducted between July 1996 and October 1998, evaluating the 
impact of PPV23 on geriatric patients, found that the majority of patients developing 
pneumonia had not received the vaccine. The study found that the vaccine significantly 
(OR 0.279; p<0.0001) reduced the risk of pneumonia. Wagner et al., in 2003 also found 
that vaccination significantly (OR 0.331; p<0.0001) reduced death associated with 
pneumonia. 
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Chapter Four 
Rational of Study and Research Objectives 
 
Rationale of Study 
 Considering that invasive pneumococcal disease is associated with antibiotic 
resistance and a higher incidence among children less than 5 years of age, it is important 
to monitor resistance patterns and incidences among this population. Knowing the trends 
and risk factors associated with invasive pneumococcal infections will allow the 
Department of Health to develop effective strategies in reducing the incidence of this 
disease. In addition information on antibiotic resistance patterns will be made available to 
the health care community. Risk factors and antibiotic resistance patterns may aid health 
care practitioners in selecting more effective antibiotics and developing more efficient 
treatment strategies for patients. 
Invasive S. pneumoniae is a reportable disease in Florida and many other states. 
Laboratory reports with antibiograms are sent to the Department of Health, Bureau of 
Epidemiology, by the county health departments. Antibiograms have proven to be a 
simple and accurate way to estimate prevalence of antibiotic-resistant pneumococci (Van 
Beneden, Lexau, Baughman, Barnes, Bennett et al., 2003). 
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Objectives 
 The objectives of this study are: 
 
1. Define the demographics of cases of invasive S. pneumoniae, in Florida in 2003. 
2. Determine the clinically relevant antibiotic resistance patterns of S. pneumoniae, 
as listed by the National Committee for Clinical Laboratory Standards (NCCLS. 
1999), in Florida in 2003. 
3. Determine if age, gender, race, region and seasonal variation are risk factors for 
development of antibiotic resistance among invasive S. pneumoniae cases in 
Florida during 2003.  
4. Determine the incidence rate of S. pneumoniae in Florida in 2003 and compare 
the incidence rate to reported data from 1999 and 2000 for the entire state to 
determine if significant changes have occurred.  
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Chapter Five 
 
Methods 
 
Study Design 
 This is a cross-sectional study of Streptococcus pneumoniae during 2003 in the 
state of Florida. Due to the lack of a control group only descriptive analysis will be 
performed. Cross-sectional studies are used to examine a specific disease within a 
population (Gordis, 2000). Data for 2003 was reported to the Bureau of Epidemiology by 
county health departments and used to form the data set for this study. 
 Institutional Review Board (IRB) approval was received, from the University of 
South Florida and the Florida Department of Health, in September 2004 prior to any 
analysis of data. Patients were not contacted at any time during this study. All 
information was obtained from laboratory reports and antibiograms provided by the 
Department of Health, Bureau of Epidemiology. Personal identifiers were removed from 
the data set prior to analysis, to comply with IRB requirements for exemption.  
 
Study Population 
 The study population is comprised of 1056 invasive S. pneumoniae cases that 
were reported to Florida Department of Health (FDOH) Bureau of Epidemiology for 
2003, as having a positive laboratory diagnosis of invasive S. pneumoniae. Ninety nine 
percent of reported cases were residents of Florida; the remaining 1% had no county of 
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residence reported. All cases will be used in the analysis of incidence, but missing values 
will be accounted for during the analysis of risk factors.  
 
Inclusion Criteria 
 Cases of invasive Streptococcus pneumoniae were included in this study only if 
they were reported to the Bureau of Epidemiology and they met the States definition for a 
case of invasive S. pneumoniae. According to the FDOH Bureau of Epidemiology, 
diagnosis is confirmed when S. pneumoniae is isolated from a normally sterile site (e.g. 
blood, cerebrospinal fluid). 
 
Data Sources 
 The dataset for this study was compiled from two different sources: (1) laboratory 
results from state labs, and (2) antibiograms received with the lab reports that were sent 
to the Bureau of Epidemiology. The majority of the reports were complete, with enough 
information necessary to construct the dataset.  
 
Data Collection 
 Lab reports were sent to the Bureau of Epidemiology throughout 2003 and into 
2004. The lab reports were reviewed by the Regional Epidemiologist to determine if the 
cases met the case definition of an invasive S. pneumoniae infection. The dataset was 
constructed at the Bureau of Epidemiology and all files were kept in the locked office of 
the Regional Epidemiologist for safekeeping. All identifying information was removed 
from the dataset prior to analysis. 
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Data Management 
 The Department of Health (DOH) database was constructed using Microsoft 
Excel. The database includes information provided by laboratory reports and 
antibiograms provided by county health departments. The information included in the 
database consists of date of report, county and county number, case number, ICD9 codes, 
last name, date of birth, age, source of the infection, type of infection, antibiotic 
resistance, gender, race, ethnicity, zip code, date of recognized infection, origin of the 
disease, occupation of the patient, and week number event occurred. The personal 
identifiers were removed from the database prior to analysis and leaving the Department 
of Health.  The data was then analyzed with Statistical Analysis Software (SAS) 
 
Definition of Variables 
 Variables that were analyzed in this study include: antibiotics, county of 
residence, gender, race, ethnicity, age, and month (season) the event occurred. All 
variables were determined by the lab reports turned into the DOH. There are 67 counties 
in the state of Florida; all counties are required to report cases of invasive S. pneumoniae 
to the State Health Department. Twenty counties either failed to report any or had no 
cases of invasive S. pneumoniae. Of the remaining 47 counties, the majority of cases 
were reported from counties with populations greater than 450,000. Gender was reported 
as; Male, Female, or Unknown. Race was reported as: American Indian/Native Alaskan, 
Asian/Pacific Islander, Black, White, Other, or Unknown. Ethnicity was reported as 
either Hispanic or Non-Hispanic. Age was collected in years, months, and days. Age was 
then divided into age groups (in years); <1, 1-2, 3-4,0-4, 5-17, 18-34, 35-49, 50-64, and 
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≥65, for comparison to previous Florida studies (Florida Department of Health, 2000). 
Finally the month in which the event occurred was used. 
 
Data Analysis 
 Descriptive epidemiology was used to describe patterns of S. pneumoniae 
infection and antibiotic resistance by class of antibiotic from January 1, 2003 to 
December 31, 2003.  Variables analyzed included age, gender, race, county, and month 
(seasonal variation), to determine risk factors for S. pneumoniae becoming resistant to 
various antibiotics.  
The population was divided into age groups as described by the Florida 
Department of Health (Florida Department of Health, 2000). Incidence of infection (per 
100,000) was calculated for each age group using the current census projections for 
population data. Considering that incidence of S. pneumoniae is lowest among those 
between 5-17, this age group was used as a reference group to demonstrate the impact of 
the bacterium on those less than 4  years old and individuals over 65 years old. 
Due to the potential for dilution of the data, only counties with populations over 
450,000 were included in the analysis of risk factors for antibiotic resistance. These 
counties include: Brevard, Broward, Miami-Dade, Duval, Hillsborough, Orange, Palm 
Beach, Pinellas, and Polk. This population limit was chosen, because these counties make 
up the majority (>70%) of cases reported. 
Frequency was calculated excluding any missing values. Assuming that any 
missing values are missing at random, these values would have no effect on the outcome. 
Logistic regression was used to find association between each risk factor and resistance 
38 
among invasive S. pneumoniae cases. Logistic regression was chosen due to the fact that 
the dependent variable (resistance) has a binary outcome (either resistant or susceptible). 
Logistic regression is an effective way to determine the relative importance of the 
independent variables. p-Values and 95% Confidence Intervals were calculated to 
determine statistical significance. Goodness of fit and residuals were examined to 
determine how well the variables fit the final model. These residual plots are located in 
appendix A. When outliers were controlled for, there was no change in how well 
variables fit the model. Statistical analysis was performed using the SAS statistical 
software.  
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Chapter Six 
Results 
 
 The results chapter is divided into three major sections. The first will cover 
incidence and epidemiologic characteristics of invasive S. pneumoniae disease, the 
second will cover the clinically relevant antibiotic resistance patterns of S. pneumoniae, 
and the third will cover risk factors for antibiotic resistance among invasive S. 
pneumoniae cases. 
 In the first section the demographics of the whole study population will be 
examined, using all 1056 cases of invasive S. pneumoniae. The second section will 
examine the portion of the cases that reported resistance to any of the 16 antibiotics that 
were included in the dataset. The third section will use the cases from Florida counties 
with populations over 450,000 persons to determine if county, gender, race, age or month 
are risk factors for resistance. 
 
Characteristics of the Study Population 
 Descriptive analysis was performed on all 1056 culture-confirmed cases of 
invasive S. pneumoniae reported during 2003 to the Florida Department of Health, 
Bureau of Epidemiology, allowing for characterization (Objective 1) of the study 
population. Cases were reported from the entire state, including 47 of 67 counties.  
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Age 
 Of the 1056 reported cases 910 reported age data. 133 reported no age type. By 
reporting no age type it was impossible to determine if a reported age was months or 
years. In addition 13 reported no age. The following graph (Figure 3) illustrates the 
distribution by age group for all Invasive S. pneumoniae cases, with age reported, in 
Florida 2003. The graph also illustrates the percentage of cases accounted for by age 
group. 
 
Figure 3: Distribution of invasive S. pneumoniae cases by age group, Florida 2003 
Cases by Age Group
0 50 100 150 200 250 300
<1 year
1-2 year
3-4 years
0-4 year
5-17 years
18-34 years
35-49 years
50-64 years
65 + years
Ag
e
Number of Cases
31%
22.4%
17.8%
6.7%
4.5%
17.5%
3.8%
7.0%
6.7%
 
Source: S. pneumoniae dataset, Florida 2003 
 
 
 Age groups were also examined to determine if there were any differences in 
percentages when looking at race, county, and penicillin resistance. The following table 
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illustrates the comparisons. Countys demonstrated similar percentages of cases by age 
group compared to that of the total population. Black race had a higher percentage 
(27.3%) among those 35 to 49 years old compared to the same age group for the total 
population (17.8%). Black race also had a lower percentage (11.6%) among those 65 
years and older compared to the overall population (31%). White race displayed slightly 
lower percentages among those less than 5 years of age while Black race demonstrated 
slightly higher percentages among the same age groups, when both were compared to the 
overall population. The majority of penicillin resistant cases occurred among individuals 
less than 4 years of age and those over 35 years of age. 
 
               Table 1: Comparison of Age, Race, and Penicillin Resistance by  
               percentage of population, Florida 2003 
    % of Number (%) by  % by 
Age 
Group Number Total  Race Penicillin 
in years in group Population     Resistance 
      Black White   
<1 61 6.7 19 (7.8) 38 (6.5) 7.56 
1-2 64 7.0 21 (8.7) 29 (4.9) 10.47 
3-4 35 3.8 13 (5.4) 15 (2.6) 6.98 
0-4 160 17.5 53 (21.9) 82 (14.0) 25.01 
5-17 41 4.5 10 (4.1) 25 (4.3) 2.91 
18-34 61 6.7 27 (11.2) 31 (5.3) 5.81 
35-49 162 17.8 66 (27.3) 82 (14.1) 16.28 
50-64 204 22.4 58 (23.9) 135 (23.2) 18.02 
65+ 282 31.0 28 (11.6) 228 (39.1) 31.98 
Total 910 100.0 242 (100) 583 (100)   
               Source: S. pneumoniae dataset, Florida 2003 
 
 The following chart (Table 2) illustrates the distribution of cases by age group 
and incidence for each age group. Over half (54%) of S. pneumoniae cases were adults 
over the age of 50 and children less than five years of age accounted for nearly 20%. 
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                           Table 2: Percentage and Incidence of S. pneumoniae cases, Florida 
                            2003 
    Number % of Incidence 
Age Group In Age  Total Rate 
    Group Cases 
Per 
100,000  
<1 year 64 6.7 34.21 
1-2 year 61 7.0 16.27 
3-4 years 35 3.8 9.11 
0-4 year 160 17.5 16.91 
5-17 years 41 4.5 1.52 
18-34 years 61 6.7 1.79 
35-49 years 162 17.8 4.54 
50-64 years 204 22.4 8.02 
≥ 65 years 282 31.0 10.04 
Total 910      100.0    
                            Source: S. pneumoniae Database, Florida 2003 
 
Gender 
 Gender information was available on all 1056 cases in the study population. 
Males (n=577) made up 55% of the population. This proportion differs slightly from the 
overall proportion of males to females in Florida, in which females account for 51.2% of 
the population and males account for 48.8%, according to U.S. census information for 
2000. Table 3 lists each age group by gender. The information in table 3 illustrates that 
while females account for a greater proportion of the over all population, proportions of 
males to females was similar among all age groups except those over 65 years of age. 
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Table 3 also illustrates that males account for a higher percentage of S. pneumoniae 
cases among all age groups except those over 65 years, and females only account for 
0.6% more cases. Table 4 displays frequency and percentage of S. pneumoniae by age 
group, sex, and race. Age groups <1, 1-2, and 3-4 dont add to the total percentage of 
cases for the combined age groups due to rounding of decimal places. 
 
                             Table 3: Percentage of S. pneumoniae cases per age group 
                              by gender, Florida 2003                              
  % of % of 
Age 
Group Study Florida 
in years Population Population 
  Male Female Male Female 
<1 4.1 2.6 0.6 0.6 
1-2 4.7 2.3 1.2 1.1 
3-4 2.0 1.9 1.2 1.2 
0-4 10.8 6.8 3.0 2.9 
5-17 3.0 1.5 8.7 8.2 
18-34 3.4 3.3 10.9 10.5 
35-49 10.1 7.7 11.0 11.3 
50-64 12.1 10.3 7.6 8.4 
65+ 15.2 15.8 7.6 10.0 
Total 54.5 45.5 48.8 51.2 
                             Source: S. pneumoniae data, Florida 2003
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Racial and Ethnic Differences 
 Racial information was available on 953 of the 1056 cases. Of these 70.5% 
(672) were white, 28.1% (268) were African-American, less than one percent were Asian, 
and less than one percent reported Other as race.  
 Ethnicity data was reported for 842 of the 1056 cases. Of these Non-Hispanic 
was reported by 84.2% (709) of the cases, and Hispanic was reported by 15.7% (133) of 
the cases. Examining ethnicity by gender, Hispanic males accounted for the majority of 
case (63%) where ethnicity was reported. The following chart (Table 5) illustrates the 
distribution of S. pneumoniae cases and penicillin resistant cases by ethnicity. The chart 
demonstrates that for both Hispanics and non-Hispanics the majority of cases occur in 
those less than four years of age and those over 50 years of age. Similar results were 
found for penicillin resistance. 
                      Table 5: Frequency and percentage of S. pneumoniae cases by  
                      Ethnicity, in Florida 2003 
          
Age 
Number of cases (%) 
by 
Penicillin Resistance (I 
+ R) 
Group Ethnicity N (%) by Ethnicity 
in 
years         
  Hispanic 
Non-
Hispanic Hispanic 
Non-
Hispanic 
<1 16 (13%) 43 (6%) 8 (13%) 29 (9%) 
1-2 16 (13%) 36 (6%) 9 (14%) 21 (7%) 
3-4 7 (6%) 22 (3%) 5 (8%) 13 (4%) 
0-4 37 (32%) 101 (15%) 22 (35%) 63 (20%) 
5-17 10 (8%) 27 (4%) 5 (8%) 11 (4%) 
18-34 4 (3%) 50 (8%) 2 (3%) 24 (8%) 
35-49 13 (11%) 114 (18%) 6 (10%) 52 (17%) 
50-64 24 (20%) 140 (22%) 10 (16%) 67 (22%) 
≥65 32 (26%) 210 (33%) 18 (28%) 89 (29%) 
Total 122 642 63 306 
                      Source: S. pneumoniae data, Florida 2003 
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Geographic Distribution 
 County information was available on 1043 of the 1056 cases. Counties with 
populations over 450,000 were examined more closely, to get a clearer picture of age 
distribution in counties with large populations. The analysis of incidence by age group 
and county will be examined more closely in later sections. Counties with an asterisk (*) 
had too few cases to calculate an accurate confidence limit. The following table (table 6) 
displays the number of S. pneumoniae cases and incidence for all 67 counties. 
 
Table 6: Number of S. pneumoniae cases and incidence by 
county, Florida 2003 
      # of Incidence Confidence 
S. 
pneumoniae Per 100,000 Limits 
COUNTY # POP cases   Lower Upper 
Alachua 1       223,578  16 7.2 3.6 10.7
* Baker 2         23,424  1 4.3 -- --
Bay 3       155,193  9 5.8 2.0 9.6
Bradford 4         26,928  0 0.0 0.0 0.0
Brevard 5       505,711  40 7.9 5.5 10.4
Broward 6    1,731,347  74 4.3 3.3 5.3
Calhoun 7         12,921  0 0.0 0.0 0.0
* Charlotte 8       153,392  1 0.7 -- --
Citrus 9       126,458  8 6.3 1.9 10.7
Clay 10       157,502  0 0.0 0.0 0.0
Collier 11       286,634  14 4.9 2.3 7.4
Columbia 12         60,244  4 6.6 0.1 13.2
Dade 13    2,341,167  147 6.3 5.3 7.3
DeSoto 14         33,879  0 0.0 0.0 0.0
Dixie 15         13,982  0 0.0 0.0 0.0
Duval 16       817,480  69 8.4 6.4 10.4
Escambia 17       295,886  24 8.1 4.9 11.4
Flagler 18         62,206  5 8.0 1.0 15.1
* Franklin 19         10,003  1 10.0 -- --
Gadsden 20         45,134  0 0.0 0.0 0.0
* Gilchrist 21         15,633  3 19.2 -- --
Glades 22         11,165  0 0.0 0.0 0.0
* Gulf 23         15,247  1 6.6 -- --
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Hamilton 24         13,917  0 0.0 0.0 0.0
* Hardee 25         27,659  2 7.2 -- --
Hendry 26         37,064  5 13.5 1.6 25.3
Hernando 27       143,449  6 4.2 0.8 7.5
* Highlands 28         91,051  2 2.2 -- --
Hillsborough 29    1,073,407  92 8.6 6.8 10.3
Holmes 30         18,986  0 0.0 0.0 0.0
Indian River 31       120,463  1 0.8 -0.8 2.5
* Jackson 32         46,508  1 2.2 -- --
* Jefferson 33         14,037  2 14.2 -- --
Lafayette 34           7,333  0 0.0 0.0 0.0
Lake 35       245,877  20 8.1 4.6 11.7
Lee 36       492,210  39 7.9 5.4 10.4
Leon 37       242,577  10 4.1 1.6 6.7
Levy 38         36,270  0 0.0 0.0 0.0
Liberty 39           7,315  0 0.0 0.0 0.0
Madison 40         18,766  0 0.0 0.0 0.0
Manatee 41       286,804  7 2.4 0.6 4.3
Marion 42       280,288  13 4.6 2.1 7.2
Martin 43       135,122  4 3.0 0.1 5.9
* Monro 44         78,940  1 1.3 -- --
Nassau 45         61,625  0 0.0 0.0 0.0
Okaloosa 46       178,104  7 3.9 1.0 6.8
Okeechobee 47         37,481  0 0.0 0.0 0.0
Orange 48       964,865  80 8.3 6.5 10.1
Osceola 49       205,870  7 3.4 0.9 5.9
Palm Beach 50    1,216,282  65 5.3 4.0 6.6
Pasco 51       388,906  24 6.2 3.7 8.6
Pinellas 52       926,146  68 7.3 5.6 9.1
Polk 53       510,458  63 12.3 9.3 15.4
Putnam 54         71,841  11 15.3 6.2 24.4
Santa Rosa 55       133,092  5 3.8 0.5 7.1
Sarasota 56       346,793  17 4.9 2.6 7.2
Seminole 57       386,374  20 5.2 2.9 7.5
* St. Johns 58       142,869  2 1.4 -- --
St. Lucie 59       213,447  11 5.2 2.1 8.2
* Sumter 60         58,875  3 5.1 -- --
Suwannee 61         36,695  0 0.0 0.0 0.0
Taylor 62         19,415  0 0.0 0.0 0.0
Union 63         14,002  0 0.0 0.0 0.0
Volusia 64       468,663  37 7.9 5.3 10.4
Wakulla 65         26,131  0 0.0 0.0 0.0
* Walton 66         46,373  1 2.2 -- --
Washington 67         21,604  0 0.0 0.0 0.0
48 
FLORIDA     17,019,068 1043 6.1 5.8 6.5
Source: S. pneumoniae data, Florida 2003 
 
Counties with populations over 450,000 were highlighted in the previous table 
and include Brevard (505,711), Broward (1,731,347), Miami-Dade (2,341,167), Duval 
(817,480), Hillsborough (1,073,407), Lee (492,210), Orange (964,865), Palm Beach 
(1,216,282), Pineallas (926,146), Polk (510,458) and Volusia (468,663). Together these 
counties make up over 70% of reported cases in 2003.  The following figure (Figure 4) 
shows the number of cases reported in the previous counties. Incidence (per 100,000) is 
indicated at the top of each column.  
 
Figure 4: Geographic distribution and incidence (per 100,000) of S. pneumoniae in 
counties with populations over 450,000, Florida 2003 
Incidence by County
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Seasonality 
 The majority of invasive S. pneumoniae cases (1043 of 1056) reported a date of 
infection. This data was used to analyze seasonal variation of S. pneumoniae. The 
following figure (Figure 5) shows the monthly distribution of cases. From this chart one 
can see a lull in the warmer months, and then a steady increase starting in fall and finally 
peaking in December. The majority of cases 41% occur between December and February. 
 
Figure 5: Percentage of S. pneumoniae cases by month, Florida 2003 
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Clinically Relevant Antibiotic Resistance Patterns 
Clinically relevant antibiotic resistance patters (Objective 2) were determined by 
analyzing several antibiotics. Antibiotics examined in this study included Penicillin, 
Azithromycin, Cefotaxime, Ceftriaxone, Cefuroxime, Chloramphenicol, Clindamycin, 
Erythromycin, Imipenem, Levofloxacin, Meropenem, Ofloxacin, Rifampin, Tetracycline, 
Trimethoprim-Sulfamethoxazole, and Vancomycin. The previous table (Table 7) shows 
each of the antibiotics examined and the results from susceptibility testing. 
 
Penicillin Susceptibility 
 The overall rate of penicillin resistant S. pneumoniae (PRSP) in Florida for 2003 
was 48.30% which is slightly lower than what was reported for Florida in 2000 (56.8%) 
(Florida Department of Health, 2000). The following table (Table 8) presents the 
breakdown of penicillin susceptibility by age group. The table shows that all age groups 
had penicillin resistance (both intermediate and fully resistant) greater than 41%, with the 
highest percentage of resistance occurring in ages four years and younger. Additionally 
the table shows that elevated incidence occurs in children less than four years old and 
adults over the age of 50 years. The highest incidence of resistance occurred in children 
less than one year of age (20.3 per 100,000), out of 186,977 children less than one year of 
age. Overall incidence rates for the population (15,982,378) were found to be 2.6 per 
100,000. 
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Table 8: Percentage and incidence (per 100,000) of PRSP by age group, Florida 2003 
       Invasive Streptococcus pneumoniae cases 
AGE GROUPS Penicillin Susceptibility 
      Susceptible (S) Intermediate 'I' and Resistant 'R' 
  Cases %     %     %   
Age In Age of Number % of of Number % of of Incidence 
(years) Group Total Susceptible Total Age Resistant Total Age of Pen R
    Cases     Group     Group   
<1 50 7% 12 2% 24% 38 5% 76% 20.3 
1-2 58 8% 20 3% 34% 36 5% 62% 9.6 
3-4 31 4% 9 1% 29% 22 3% 71% 5.7 
0-4 139 19% 41 6% 29% 96 13% 69% 10.1 
5 - 17 34 5% 15 2% 44% 19 3% 56% 0.7 
18 - 34 50 7% 23 3% 46% 27 4% 54% 1.4 
35 - 49 130 18% 64 9% 49% 66 9% 51% 1.8 
50 - 64 162 22% 68 9% 42% 94 13% 58% 3.7 
≥65 223 30% 108 15% 48% 117 16% 52% 4.2 
TOTAL 738 100% 319 43%   419 57%   2.6 
Source: S. pneumoniae data, Florida 2003 
 
Drug Susceptibility 
 Resistance information was provided for several antibiotics for this study. Table 7 
shows each of the antibiotics examined. For each antibiotic the number of cases that were 
tested for susceptibility is listed, as well as the susceptibility results. Of the 1056 cases 
tested for resistance 535 (51%) were resistant to one or more antibiotics, and thus 
classified as drug resistant S. pneumoniae (DRSP) as defined by the CDC. 
The antibiotics were divided into 8 major classes; Penicillins, Macrolides 
Cephalosporins, Fluoroquinolones, Lincosamides, TMP/SMX, Tetracycline and 
Glycopeptides. Table 9 summarizes S. pneumoniae cases resistant to specific antibiotics
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55 
by age group. Vancomycin is a glycopeptide, and was not reported in the table due to the 
fact that no cases reported either intermediate or high levels of resistance. These specific 
antibiotics were chosen because more data was available on these drugs. 
 
Multi-Drug Resistance 
 Combinations of drug resistance were analyzed for those records with reported 
susceptibility for the antibiotics (N=154): penicillin, ceftriaxone, erythromycin, 
tetracycline, TMP/SMX, and chloramphenicol. The most common pattern of multi-drug 
resistance was observed for resistance to penicillin, erythromycin, and TMP/SMX. This 
information is displayed in Table 10.
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Macrolides 
 Erythromycin resistant strains of S. pneumoniae have been shown to also exhibit 
resistance to penicillin and other Macrolides including azithromycin. Of the 626 isolates 
tested for erythromycin susceptibility 222 (33.87%) were resistant (either intermediate or 
fully resistant). Of these 99 (49%) were fully resistant to penicillin and 79 (39%) 
displayed intermediate resistance to penicillin. Azithromycin susceptibility was reported 
on 36 (16.21%) of the 222 erythromycin cases. Of these isolates 32 (88.8%) displayed 
resistance to erythromycin. 
 
Cephalosporins 
 The cephalosporins that were analyzed for this study were Cefotaxime, 
Ceftriaxone are third generation cephalosporins and Cefuroxime which is a second 
generation cephalosporin. These antibiotics have been shown to display low levels of 
resistance (<10%) in penicillin susceptible strains, with some increased percentage of 
resistance (~50%) in PRSP strains (Florida Department of Health, 2000). 512 isolates 
were tested for susceptibility of Cefotaxime, 47 (9.17%) were reported as being resistant 
(I and R). Of these that were also tested for penicillin susceptibility, 44 (93.61%) were 
resistant (I and R). 635 isolates were tested for susceptibility to Ceftriaxone, of these 34 
(5.35%) were resistant. Of these 34 strains, 33 (97%) demonstrated resistance to 
penicillin. Susceptibility was also reported for Cefuroxime; 58 (32.76%) of 177 isolates 
were found to be resistant. Of these 58 cases, 57 (98.27%) were also found to have 
intermediate or full resistance to penicillin. 
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Fluoroquinolones 
 Levofloxacin and Ofloxacin are Fluoroquinolones that were examined in this 
study. Ofloxacin is a first generation, while Levofloxacin is a second generation. 
Ofloxacin is not the best choice of treatment due to its poor susceptibility performance 
(Florida Department of Health, 2000). Levofloxacin is currently an appropriate treatment 
choice for outpatients or admitted patients with S. pneumoniae pneumonia (Shah, 
Gidudice, Griesback Jr, Morley, & Vasoya, 2004).  
 Susceptibility to Levofloxacin was reported for 342 cases. Of these 342 cases 
seven (2%) were classified as being resistant (I and R). Cases that were tested for both 
Penicillin and Levofloxacin yielded three of seven (42.8%) cases resistant (I and R) to 
both. 
 
Trimethoprim Sulfamethoxazole 
 Trimethoprim Sulfamethoxazole (TMP/SMX) is reported to have elevated 
resistance levels along with Penicillin resistance. This drug is not the most appropriate 
choice in treatment of S. pneumoniae. 
 Susceptibility of TMP/SMX was reported for 529 cases. Among these 529 cases 
198 (37.43%) were reported as resistant (I and R). Cases that were tested for both 
Penicillin and TMP/SMX, 248 reported resistance to penicillin and 186 (75%) reported 
co-resistance to TMP/SMX. 
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Tetracycline 
 Tetracycline resistance has been on the rise in Florida since 1979 (Florida 
Department of Health, 2000). There were 359 cases with data for tetracycline, resistance 
was reported in 47 (13.09%). Cases reporting tetracycline and resistance to penicillin 
numbered 176, of these 43 (24.43%) reported co-resistance to tetracycline. 
 
Vancomycin 
 Currently there have been no reports of a case of S. pneumoniae being resistant to 
vancomycin (Pallares, Fenoll, & Linares, 2003). A recent study in Mississippi reported 
two cases of S. pneumoniae being tolerant to vancomycin (Gillis, White, Whitehurst, & 
Sullivan, 2005).  
 Susceptibility for vancomycin was reported for 797 cases. 100% were susceptible 
to vancomycin. 
 
Risk Factors for Antibiotic Resistance 
 The variables that were examined as potential risk factors (Objective 3) for 
antibiotic resistance include; gender, race, age group, and month. Logistic regression was 
performed to determine which if any of these factors posed a risk. The following table 
(Table 11) summarizes all results from the logistic regression model.
60
 
   
   
   
   
   
   
   
   
   
   
  T
ab
le
 1
1:
 M
ax
im
um
 L
ik
el
ih
oo
d 
Es
tim
at
es
 a
nd
 C
on
fid
en
ce
 L
im
its
 fr
om
 lo
gi
st
ic
 re
gr
es
sio
n,
 F
lo
rid
a 
20
03
 
  
  
M
ax
im
um
 L
ik
el
ih
oo
d 
  
  
95
 %
 W
al
d 
V
ar
ia
bl
e 
Es
tim
at
es
 
p-
va
lu
e 
O
dd
s 
R
at
io
 
C
on
fid
en
ce
 
lim
its
 
  
  
Es
tim
at
e
St
an
da
rd
 E
rr
or
 
  
  
Lo
w
er
 
U
pp
er
 
G
en
de
r 
M
al
e 
0.
03
65
 
0.
09
15
 
0.
68
96
 
1.
07
6 
0.
75
2 
1.
54
 
  
 
 
 
 
 
 
  
R
ac
e 
W
hi
te
 
0.
05
03
 
0.
31
67
 
0.
87
39
 
0.
90
2 
0.
56
9 
1.
36
4 
  
O
th
er
 
-0
.2
03
8 
0.
60
64
 
0.
73
68
 
0.
69
9 
0.
11
5 
4.
24
7 
  
 
 
 
 
 
 
  
A
ge
 
G
ro
up
 
≤ 
1 
ye
ar
 
0.
65
 
0.
39
1 
0.
09
65
 
3.
07
7 
0.
96
9 
9.
76
6 
  
1-
2 
ye
ar
 
0.
26
09
 
0.
35
23
 
0.
45
9 
2.
08
5 
0.
70
4 
6.
17
3 
  
3-
4 
ye
ar
 
0.
15
58
 
0.
45
76
 
0.
73
36
 
1.
87
7 
0.
52
6 
6.
69
9 
  
18
-3
4 
ye
ar
s 
0.
06
77
 
0.
32
02
 
0.
83
26
 
1.
71
9 
0.
61
 
4.
84
5 
  
35
-4
9 
ye
ar
s 
-0
.3
94
 
0.
21
64
 
0.
06
87
 
1.
08
3 
0.
44
7 
2.
62
8 
  
50
-6
4 
ye
ar
s 
-0
.1
82
4 
0.
20
27
 
0.
36
8 
1.
33
8 
0.
56
2 
3.
18
8 
  
≥ 
65
 y
ea
rs
 
-0
.0
83
9 
0.
19
33
 
0.
66
44
 
1.
47
7 
0.
62
7 
3.
47
8 
Fe
m
al
e 
ge
nd
er
, B
la
ck
 R
ac
e,
 5
-1
7 
ye
ar
 o
ld
s, 
an
d 
Ju
ly
 w
er
e 
us
ed
 a
s r
ef
er
en
ce
 g
ro
up
s 
   
   
   
   
   
   
   
   
   
   
   
So
ur
ce
: S
. p
ne
um
on
ia
e 
da
ta
, F
lo
rid
a 
20
03
 
     
61
 
   
   
   
   
   
   
   
   
   
   
 T
ab
le
 1
1:
 M
ax
im
um
 L
ik
el
ih
oo
d 
Es
tim
at
es
 a
nd
 C
on
fid
en
ce
 L
im
its
 fr
om
 lo
gi
st
ic
 re
gr
es
sio
n,
 F
lo
rid
a 
20
03
 
  
  
M
ax
im
um
 L
ik
el
ih
oo
d 
  
  
95
 %
 W
al
d 
V
ar
ia
bl
e 
Es
tim
at
es
 
p-
va
lu
e 
O
dd
s 
R
at
io
 
C
on
fid
en
ce
 li
m
its
  
  
Es
tim
at
e
St
an
da
rd
 E
rr
or
 
  
  
Lo
w
er
U
pp
er
 
M
on
th
 
Ja
nu
ar
y 
0.
36
23
 
0.
27
86
 
0.
19
65
 
4.
74
7 
2.
14
2 
10
.5
17
 
  
Fe
br
ua
ry
 
-0
.1
24
4 
0.
26
26
 
0.
63
57
 
2.
91
8 
1.
34
5 
6.
32
7 
  
M
ar
ch
 
2.
84
74
 
0.
93
07
 
0.
00
22
 
56
.9
72
 
7.
21
 
45
0.
15
2 
  
A
pr
il 
1.
23
73
 
0.
44
72
 
0.
00
57
 
11
.3
87
 
3.
80
8 
34
.0
5 
  
M
ay
 
0.
68
33
 
0.
39
62
 
0.
08
46
 
6.
54
3 
2.
39
9 
17
.8
42
 
  
Ju
ne
 
0.
05
99
 
0.
39
6 
0.
87
97
 
3.
50
8 
1.
29
 
9.
54
2 
  
A
ug
us
t 
-0
.3
59
8 
0.
36
14
 
0.
31
94
 
2.
30
5 
0.
9 
5.
90
4 
  
Se
pt
em
be
r
-0
.3
61
1 
0.
33
82
 
0.
28
55
 
2.
30
3 
0.
94
3 
5.
62
3 
  
O
ct
ob
er
 
-1
.0
02
7 
0.
27
79
 
0.
00
03
 
1.
21
2 
0.
54
8 
2.
68
 
  
N
ov
em
be
r 
-1
.3
01
1 
0.
27
67
 
<0
.0
00
1 
0.
89
9 
0.
40
6 
1.
99
3 
  
D
ec
em
be
r 
-0
.8
46
 
0.
23
2 
0.
00
03
 
1.
41
8 
0.
68
6 
2.
92
9 
Fe
m
al
e 
ge
nd
er
, B
la
ck
 R
ac
e,
 5
-1
7 
ye
ar
 o
ld
s, 
an
d 
Ju
ly
 w
er
e 
us
ed
 a
s r
ef
er
en
ce
 g
ro
up
s 
   
   
   
   
   
   
   
   
   
   
   
So
ur
ce
: S
. p
ne
um
on
ia
e 
da
ta
, F
lo
rid
a 
20
03
 
62 
 Age was analyzed comparing all age groups to 5-17 year olds. The 5-17 year age 
group was used as the reference group because it demonstrated the lowest incidence. The 
likelihood of DRSP for age less than 1 (OR=3.1 CI 0.97 - 9.8), age 1-2 years (OR = 2.1 
CI 0.70 - 6.2) and age greater than 65 years (OR = 1.5 CI 0.63 - 3.5). These results were 
not significant. 
 Race was analyzed using Black race as the reference group. No association was 
found between race and DRSP.  
  For gender, males posed no greater risk than females (OR = 1.1 CI 0.8-1.5). 
These results were also found to be non-significant. 
 Using the binary logit model, only month of occurrence was found to be a 
significant factor (p<.0001). Using July as the reference group, all other months were 
examined for increased risk of resistance. Cases occurring any month except November 
were more likely to have a resistant strain. The only significant results occurred in 
October (OR 1.2, 95% CI 0.5  2.6), November (OR .9, 95% CI 0.4  2.0), and 
December (OR 1.4, 95% CI 0.7  2.8).  These odd ratios do not demonstrate a dramatic 
increase in the likelihood of DRSP among these months. 
 Another analysis was preformed, dividing the months into four seasons: Spring 
(March, April, and May), summer (June, July, and August), autumn (September, October, 
and November) and winter (December, January, and February). Using logistic regression, 
there was a significant difference between the likelihood of DRSP for spring (OR 0.1, 
95% CI 0.05 - 0.2). Once again the OR did not demonstrate a dramatic increase in the 
likelihood of DRSP during spring. 
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Incidence of Streptococcus pneumoniae 
 For the calculation of incidence of S. pneumoniae (Objective 4), all cases reported 
to the state Bureau of Epidemiology were included. Cases reported covered the entire 
year of 2003 for the state of Florida. 
 The incidence of invasive pneumococcal disease was calculated to be 6.61 per 
100,000 persons (95% CI 6.21  7.01).  
 
Incidence by Age group 
 Incidence was calculated using 2003 population estimates obtained from the 
United States Census Bureau. Incidence rates for all age groups are shown in Figure 6. 
Incidence was highest among children less than one (34.21/100,000). Incidence was also 
elevated among children less than 4 years of age and in adults over 65.  
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Figure 6: Incidence of S. pneumoniae by age group, Florida 2003  
Incidence by Age Group
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Incidence by Gender and Race 
 Incidence among males, 7.4 per 100,000 persons (95 % CI 6.8  8.0) was higher 
than that of females, 5.9 per 100,000 (95% CI 5.3  6.4).  
 Incidence among black race, 11.5 per 100,000 (95% CI 10.1  12.9), was twice 
that of whites, 5.4 per 100,000 (95% CI 5.0  5.8).  
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Chapter Seven 
 
Discussion 
 
Limitations of the Study 
   This is the only population-based S. pneumoniae data source that includes the 
entire state of Florida. So there are several reporting issues that can cause limitations in 
the analysis of the data. 
Selection bias may be introduced due to incorrect reporting by hospitals; there is 
the potential for accurate reporting of resistant cases and under reporting of case that 
report no resistance. This potential discrepancy in reporting would resort in the over 
estimation of antibiotic resistance. Furthermore laboratories and providers that fail to 
report cases of invasive S. pneumoniae to the Department of Health or laboratories that 
file incomplete reports can introduce bias.  The lack of a quality assurance program to 
insure data quality is also a limitation. 
 Unfortunately for this study it is impossible to create an accurate control group, 
because of the possibility of incomplete reporting. Considering that the main goal of this 
study was descriptive analysis of the study population, one of the significant limitations 
was the lack of reporting of vaccine coverage. Vaccine coverage information would be 
valuable in determining efficacy of the vaccine in reducing incidence. 
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 A limitation in the determination of risk factors and calculation of incidence is the 
potential for missing cases and missing variables. Both of these factors contribute to 
underestimation of risk factors and incidence. 
 
Strengths of the Study 
 Considering that invasive pneumococcal disease is associated with antibiotic 
resistance and a higher incidence among children less than 5 years of age, it is important 
to monitor resistance patterns and incidence among this population. One of the strengths 
of this study is that it examines cases on a state wide level, not just by county. This aids 
in determining problem areas within the state.  
This study defines the trends and risk factors associated with antibiotic resistance 
among invasive pneumococcal infections. Applying this information will allow the 
Department of Health to develop effective strategies in reducing the incidence of this 
disease. In addition antibiotic resistance patterns were defined and will be made available 
to the health care community.  
Risk factors and antibiotic resistance patterns may aid health care practitioners in 
selecting more effective antibiotics and developing more efficient treatment strategies for 
patients. 
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Interpretation of Results 
Characteristics of the Study Population 
 Comparing the results from this study with previous studies there are several 
occurrences of interest. 
 The proportion of males was 54.6%. This is consistent with the number of males 
with infection in comparison with previous years in Florida, males accounted for 52.3% 
of cases in 2000 and 53.3% of cases in 1999 (Florida Department of Health, 2000). When 
examining Hillsborough County alone, males accounted for a lower percentage (53%) 
when compared to a 1997 study which reported 58% (Walker & Sanderson, 1998).  A 
survey of Central Florida from July 1997 thru March 1999 reported 55.9% of cases were 
male, which is higher than the 50% reported for 2003. These proportions are consistent 
with previous analysis of data for the U.S. in which males accounted for 55% of cases 
(Robinson et al., 2001). 
 Overall incidence of infection was 6.6/100,000 for 2003, this is a decrease from 
that reported by the state in 2000 (11.2 per 100,000). The highest incidence of infection 
occurs in children less than 4 years of age and adults over 65. Incidence was especially 
high among children <1 year of age (34.21/100,000). This number was lower than the 
Robinson study found in 1995-1998, which reported a pre-vaccine incidence of 
166.9/100,000, in children less than 2 years (Robinson et al., 2001). The incidence is also 
lower than the CDCs report for 2003, of 39.3/100,000, for persons <1 year of age (CDC, 
2004).   
Children less than 5 years of age accounted for 18% of cases. This is a decrease 
from previous Florida reports, in 2000 40% of the cases were reported in children less 
68 
than 5 years old (Florida Department of Health, 2000).  Hillsborough County also 
showed a similar decrease in percentage among those less than 5 years of age, 22% in 
2003 down from 42% in 1997 (Walker & Sanderson, 1998). A survey of central Florida 
form July 1997-March 1999 reported 42% of cases occurred among children less than 5 
years of age, which is greater than the 17% that was reported in 2003. Once again this is 
most likely due to the introduction of the PCV vaccine. 
 The results from this study also demonstrated whites accounting for a higher rate 
(71.5%) of cases and lower incidence 5.39/100,000 (95% CI 4.98-5.8), where race was 
reported. It is interesting to note that even though blacks made up a smaller proportion, 
incidence was higher among this group 11.48/100,000. This is possibly due to a higher 
proportion of cases occurring among blacks aged 35 to 49 years, in which studies have 
shown lower vaccine coverage compared to those over 65 years of age. These results are 
consistent with previous studies (Pastor et al., 1998) and (Robinson et al., 2001). 
 Seasonal variation is consistent with other reports, with the highest number of 
cases being reported during the winter months of November through February. These 
findings are consistent with results from the Kim and Dowell studies. Both of which 
reported peaks in the number of cases in the winter months, especially December (Kim et 
al., 1996) (Robinson et al., 2001).  
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Findings of Invasive Streptococcus pneumoniae 
 The overall incidence for invasive S. pneumoniae was calculated using 2003 
population estimates for Florida, this information is illustrated in table 5. The incidence 
was 6.13 per 100,000 Florida residents (95% CI 5.76-6.50). This incidence is lower than 
the 11.2/100,000 that was reported in Florida in 2000 (Florida Department of Health, 
2000). Floridas overall incidence is also lower than that which was reported by the CDC 
for 2003, 13.9/100,000 persons (CDC, 2004). Hillsborough countys incidence was 8.6 
per 100,000 (95% CI 6.8-10.3) which was higher than that of the entire state. Although 
incidence in Hillsborough county was down from the 16.9 per 100,000 reported in 1997 
(Walker & Sanderson, 1998). The incidence found in this study shows a similar trend to 
what was reported by Whitney in 2003, a decreasing trend in incidence since the 
introduction of the pneumococcal polysaccharide vaccine (PCV) in 2000 (Whitney, 
Farley, Hadler, Harrison, Bennett et al., 2003).  
 This study found an estimated incidence for children less than one year of age to 
be 34.21 per 100,000 children in Florida in this age group. Population data from 2000 
was used to calculate incidence for age groups and other demographics. This is similar to 
the 39.3/100,000 persons incidence that was reported by the CDC for 2003 (CDC, 2004). 
Children less than 1 year of age in the Whitney study had an incidence of 59.0/100,000 
persons in 2001 (Whitney et al., 2003). Walker and Sanderson found in Hillsborough 
County for 1997 that children less than four years of age had an incidence of 142.7 per 
100,000 (95% CI 114.0-171.4). This study found an incidence of 16.9 per 100,000 (95% 
CI 14.3-19.5) in the same age group for Hillsborough county. These decreases in 
incidence are most likely due to the use of the PCV vaccine. 
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Findings of Antibiotic Resistance 
 
 This study found that 19.7% of cases were fully resistant to penicillin. When 
cases that showed intermediate resistance are added the percentage jumps to 48.3%. The 
Florida Department of Health reported in 2000 that the overall rate of penicillin resistant 
S. pneumoniae (PRSP) was 56.8%. A study of Hillsborough County during 1997 reported 
PRSP rates of 38%. A survey conducted of Miami-Dade County in 1998, of community 
acquired infections also reported PRSP rates of 38%. Another study conducted of central 
Florida from July 1997 thru March 1999, found PRSP rates for community acquired 
infections to be 38%. These resistance percentages include both intermediate and fully 
resistant cases. 
Children less than four years of age had the highest rate (61%) resistant to 
penicillin. This rate is slightly lower than the 65% that was reported in Florida for 2000. 
These decreases in DRSP rates are most likely due to the PCV vaccine. 
 In addition to penicillin resistance, this study examined multiple resistant cases. 
Penicillin/Erythromycin/Trimethoprim Sulfamethoxazole had 23 cases, but made up the 
highest percentage of multiresistant patterns.  These results are similar to a study by 
Walker in Hillsborough County in 1998, which had the combination of 
Penicillin/Erythromycin/Trimethoprim Sulfamethoxazole occurring most frequently 
(Walker & Sanderson, 1998).   
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Summary of Chance, Bias and Confounding 
 This study was a descriptive analysis with minor analytic analysis of invasive S. 
pneumoniae cases in Florida, for 2003. Due to missing values and a small data set it was 
difficult to make any statistically significant association involving risk factors for DRSP.  
 Information bias was a potential issue in the analysis too. In regards to antibiotic 
susceptibility hospitals most likely reported more antibiotic resistant cases than 
susceptible cases. This likely resulted in the overestimation of resistance.  
 
Conclusions 
 This study demonstrates that Florida is experiencing a decrease in the proportion 
of resistance among reported cases of invasive S. pneumoniae. Considering the recent 
introduction of a vaccine for children, this trend is a good sign. These results are 
consistent with current findings that show a decrease in both those less than four years of 
age and those over 65 (Centers for Disease Control and Prevention, 2005). In addition to 
the reduction in resistance since 2000 there was also a decline in incidence. Not only is 
the incidence for 2003 (6.13/100,000) less than that reported in 2000 (11.2/100,000), it is 
also about half of that reported by the CDC for the U.S. in 2003 (13.9/100,000). This 
reduction in incidence is potentially another sign that the vaccines could be having their 
desired effect. 
 Reporting measures should continue and in addition be expanded to include 
testing for specific isolates and vaccination history. This step should be taken to 
determine if the vaccines are reducing the targeted isolates, and also to determine if new 
isolates are taking their place. Following recommendations from the CDC and NCCLS, 
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susceptibility testing should be conducted for all isolates from normally sterile sites. In 
addition to penicillin a broad spectrum cephalosporin should be tested to continually 
monitor changes in resistance. 
 There is a definite need to continually monitor this disease in the State of Florida. 
In conclusion with increased vaccine coverage and appropriate antibiotic use, DRSP 
cases might continue to decline.  
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